Cargando…

Remdesivir

Remdesivir, marketed under the brand name Veklury, is an antiviral drug with a broad spectrum of activity. There were various countries where the use of Remdesivir for the treatment of COVID-19 was authorized during the pandemic. Remdesivir was first designed to treat hepatitis C, but it was later t...

Descripción completa

Detalles Bibliográficos
Autores principales: Bakheit, Ahmed H., Darwish, Hany, Darwish, Ibrahim A., Al-Ghusn, Ahmed I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910426/
https://www.ncbi.nlm.nih.gov/pubmed/37061276
http://dx.doi.org/10.1016/bs.podrm.2022.11.003
_version_ 1784884777503948800
author Bakheit, Ahmed H.
Darwish, Hany
Darwish, Ibrahim A.
Al-Ghusn, Ahmed I.
author_facet Bakheit, Ahmed H.
Darwish, Hany
Darwish, Ibrahim A.
Al-Ghusn, Ahmed I.
author_sort Bakheit, Ahmed H.
collection PubMed
description Remdesivir, marketed under the brand name Veklury, is an antiviral drug with a broad spectrum of activity. There were various countries where the use of Remdesivir for the treatment of COVID-19 was authorized during the pandemic. Remdesivir was first designed to treat hepatitis C, but it was later tested for Ebola virus sickness and Marburg virus infections. Remdesivir is a prodrug designed to facilitate the intracellular transport of GS-441524 monophosphate and its subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase. The objective of this chapter is to provide a comprehensive review of Remdesivir (GS-5734), including its nomenclature, physiochemical properties, preparation methods, identification procedures, numerous qualitative and quantitative analytical techniques, ADME profiles, and pharmacological effects. In addition, the chapter provides a variety of chromatographic and spectroscopic techniques for separating brimonidine from other drugs in combination formulations.
format Online
Article
Text
id pubmed-9910426
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-99104262023-02-10 Remdesivir Bakheit, Ahmed H. Darwish, Hany Darwish, Ibrahim A. Al-Ghusn, Ahmed I. Profiles Drug Subst Excip Relat Methodol Article Remdesivir, marketed under the brand name Veklury, is an antiviral drug with a broad spectrum of activity. There were various countries where the use of Remdesivir for the treatment of COVID-19 was authorized during the pandemic. Remdesivir was first designed to treat hepatitis C, but it was later tested for Ebola virus sickness and Marburg virus infections. Remdesivir is a prodrug designed to facilitate the intracellular transport of GS-441524 monophosphate and its subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase. The objective of this chapter is to provide a comprehensive review of Remdesivir (GS-5734), including its nomenclature, physiochemical properties, preparation methods, identification procedures, numerous qualitative and quantitative analytical techniques, ADME profiles, and pharmacological effects. In addition, the chapter provides a variety of chromatographic and spectroscopic techniques for separating brimonidine from other drugs in combination formulations. Elsevier Inc. 2023 2023-02-09 /pmc/articles/PMC9910426/ /pubmed/37061276 http://dx.doi.org/10.1016/bs.podrm.2022.11.003 Text en Copyright © 2023 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Bakheit, Ahmed H.
Darwish, Hany
Darwish, Ibrahim A.
Al-Ghusn, Ahmed I.
Remdesivir
title Remdesivir
title_full Remdesivir
title_fullStr Remdesivir
title_full_unstemmed Remdesivir
title_short Remdesivir
title_sort remdesivir
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910426/
https://www.ncbi.nlm.nih.gov/pubmed/37061276
http://dx.doi.org/10.1016/bs.podrm.2022.11.003
work_keys_str_mv AT bakheitahmedh remdesivir
AT darwishhany remdesivir
AT darwishibrahima remdesivir
AT alghusnahmedi remdesivir